US 11,793,890 B2Granted

ELOVL2 constructs for human gene therapy

AssigneeVisgenx, Inc.

InventorsChristopher Chavez, Martin Emanuele

Life of this patent

Estimating the term…

Abstract

Disclosed herein are therapeutic agents capable of increasing the expression level of ELOVL2. Also described herein are therapeutic agents that reduce or slow an aging phenotype. Methods for treating age-related eye diseases or conditions are also provided. Methods for treating an age-related eye disease or condition in a subject by administering one or more therapeutic agents are provided.

Claims19

Dependent claims

A composition comprising a codon optimized polynucleotide sequence exhibiting at least 95% identity to SEQ ID NO:

Dependencies are inferred from the claim text.

Facts

Application: 17/821,976Filed 24 Aug 2022 · continuation
Priority: 22 Oct 2020
Published: US 2023/0065365 A12 Mar 2023
Granted: 24 Oct 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61K 48/0066
Characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered: manipulation of the nucleic acid to…
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy:…

Family

Application63/104,169Us provisional application · filed 22 Oct 2020
PCT/US2021/055648Parent of this continuation · filed 19 Oct 2021
US 2023/0065365 A1Pre-grant publication · published 2 Mar 2023
US 11,793,890 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results